AnnuaireContact
Fermer le menu

AUROBAC THERAPEUTICS

LinkedInEmail

 

Member of Lyonbiopole

 

AUROBAC THERAPEUTICS is a biopharmaceutical company created in 2022 by 3 renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux, to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings.

We focus our efforts to develop the next generation of antimicrobial and acute care products, following a targeted precision medicine approach, i.e. associated with rapid diagnostics to support product use.

 

Application market: Infectious Diseases

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Others

Created on nov. 10th, 2021 - 10 employees

 

Address

29 Avenue Tony Garnier 69007 Lyon

 

Contacts

Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.

AUROBAC THERAPEUTICS recrute

Quality Assurance Manager

Postée le 21 octobre 2024

Data Science Intern

Postée le 21 octobre 2024

Actualités récentes

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

➡ Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICS
➡ Dr Perros becomes Chairman of the Board
➡ These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization

24 juil. 2023

Bâtiment EKLAA

63 avenue Tony Garnier

69007 Lyon